Chronic Inducible Urticaria - Pipeline Insight, 2024

This “Chronic Inducible Urticaria - Pipeline Insight, 2024,” report provides comprehensive insights about companies and pipeline drugs in the Chronic Inducible Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Inducible Urticaria Understanding

Chronic Inducible Urticaria : Overview

Chronic Urticaria is the daily or episodic occurrence of weals, angioedema, or both for 6 weeks or more . Chronic urticaria can persist for a duration ranging from a few months to many years. Urticaria is a mast cell-driven. Chronic inducible urticaria is chronic urticaria that has an attributable cause or trigger and is classified according to the stimulus that provokes weals to develop. Commonly, these stimuli that provoke weals to develop include stroking or scratching the skin (dermographism), exercise, and emotional upset. Less common forms of chronic inducible urticaria are triggered by cold, heat, pressure, sunlight (solar urticaria), contact with water or various chemicals (contact urticaria), or vibration. Chronic Inducible urticaria can result in sleep deprivation, anxiety, depression, lack of energy, and social isolation and result in a significant deterioration in the quality of life.

Symptoms
Chronic inducible urticaria is particularly characterized by red or skin coloured wheals, Hives and angioedema, severe itching, painful swelling of the lips.

Diagnosis
Chronic inducible urticaria is diagnosed through the taking of a careful history and examination; this diagnosis is based on a history of daily or episodic wheals for more than 6 weeks that have been induced by an external stimulus. The diagnosis of chronic inducible urticaria relies on provocation testing and then compiling a thorough history covering. Provocation testing is used to determine the relevant triggers and to assess trigger thresholds.

Treatment
Treatment aims to control symptoms.The approach to the management of chronic inducible urticaria can involve: Avoidance of trigger factors, Induction of tolerance, Pharmacological treatment to prevent mast cell mediator release or to prevent the effects of mast cell mediators. Intermittent or continuous treatment with H1-antihistamines is recommended. Non-sedating antihistamines are preferred to older antihistamines, which have anticholinergic effects and sedative actions.

Chronic Inducible Urticaria Emerging Drugs Chapters

This segment of the Chronic Inducible Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Inducible Urticaria Emerging Drugs

CDX-0159: Celldex Therapeutics CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. The Company plans to initiate Phase 1b studies of CDX-0159 in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU).

Chronic Inducible Urticaria : Therapeutic Assessment

This segment of the report provides insights about the different Chronic Inducible Urticaria drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Inducible Urticaria

There are key companies which are developing the therapies for Chronic Inducible Urticaria . The companies which have their Chronic Inducible Urticaria drug candidates in the mid to advanced stage, i.e. Phase II and phase I/II include Celldex and others.

Phases

This report covers products under different phases of clinical development like

• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Inducible Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Inducible Urticaria : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Inducible Urticaria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Inducible Urticaria drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Inducible Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Inducible Urticaria .

Chronic Inducible Urticaria Report Insights

• Chronic Inducible Urticaria Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Inducible Urticaria Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Inducible Urticaria drugs?
• How many Chronic Inducible Urticaria drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Inducible Urticaria ?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Inducible Urticaria therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Inducible Urticaria and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Celldex Therapeutics
• Allakos

Key Products

• AK400
• CDX0159

This product will be delivered within 2 business days.